Cangrelor Intermediate CAS 163706-58-9 Purity >98.5% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Cangrelor Intermediate (CAS: 163706-58-9) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Cangrelor Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | Cangrelor Intermediate |
| Synonyms | Cangrelor Metabolite; Cangrelor Impurity 3; Cangrelor Triol Impurity; (2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-((2-(Methylthio)ethyl)amino)-2-((3,3,3-Trifluoropropyl)thio)-9H-Purin-9-yl)tetrahydrofuran-3,4-Diol; N-[2-(Methylthio)ethyl]-2-[(3,3,3-Trifluoropropyl)thio]-Adenosine |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 163706-58-9 |
| Molecular Formula | C16H22F3N5O4S2 |
| Molecular Weight | 469.50 |
| Melting Point | 179.0~181.0℃ |
| Density | 1.70±0.10 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Cangrelor / Cangrelor Tetrasodium |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | Light Yellow or Yellow Powder |
Complies |
| Water by Karl Fischer | <0.50% | 0.30% |
| Purity / Analysis Method | >98.5% (HPLC) | 98.8% |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Cangrelor / Cangrelor Tetrasodium | |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-((2-(Methylthio)ethyl)amino)-2-((3,3,3-Trifluoropropyl)thio)-9H-Purin-9-yl)tetrahydrofuran-3,4-Diol (CAS: 163706-58-9) is an intermediate of Cangrelor (CAS: 163706-06-7) and Cangrelor Tetrasodium (CAS: 163706-36-3).
On June 22, 2015, the U.S. Food and Drug Administration (FDA) approved Kengreal (Cangrelor), an intravenous antiplatelet drug that prevents harmful blood clot formation in the coronary arteries, the blood vessels that supply blood flow to the heart. It is approved for performing percutaneous coronary intervention (PCI) in adult patients, a procedure used to open a blocked or narrowed coronary artery to improve blood flow to the heart muscle.
Indications and uses
Kengreal (Cangrelor) is a P2Y12 platelet inhibitor and is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce perioperative myocardial infarction (MI) and repeat coronary revascularization in patients who have not received P2Y12 platelet inhibitors and are not receiving a glycoprotein IIb/IIIa inhibitor, and stent thrombosis (ST) risk.
Cangarello is an intravenous platelet inhibitor with a rapid onset and short half-life compared to the oral platelet inhibitor Clopidogrel. The effect of Cangarello was sustained for 1 hour after intravenous infusion was stopped, and platelet function returned to normal after 1 hour, while the effect of oral antiplatelet drugs lasted for 1 day after withdrawal.
